AstraZeneca (LON:AZN) Earns Buy Rating from Jefferies Financial Group

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reaffirmed by equities researchers at Jefferies Financial Group in a report released on Wednesday, October 7th, Digital Look reports. They currently have a £175 target price on the biopharmaceutical company’s stock. Jefferies Financial Group’s target price would suggest a potential upside of 42.28% from the stock’s previous close.

AZN has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a £117 price objective on shares of AstraZeneca in a report on Tuesday, September 29th. Berenberg Bank reiterated a “buy” rating and issued a £175 target price on shares of AstraZeneca in a research note on Wednesday, October 7th. Royal Bank Of Canada reissued an “outperform” rating and set a £145 target price on shares of AstraZeneca in a research report on Tuesday, September 8th. Finally, Citigroup boosted their price target on AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research note on Tuesday, July 28th. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of £153.57.

AstraZeneca Stock Performance

LON:AZN traded up GBX 404 during trading hours on Wednesday, hitting £123. 2,104,305 shares of the company traded hands, compared to its average volume of 28,737,752. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 64.10. AstraZeneca has a twelve month low of £114.04 and a twelve month high of £157.32. The firm has a 50-day moving average of £120.59 and a 200 day moving average of £131.66. The stock has a market capitalization of £190.76 billion, a price-to-earnings ratio of 18.41, a P/E/G ratio of 0.86 and a beta of 0.20.

Insider Activity at AstraZeneca

In other AstraZeneca news, insider Michel Demare acquired 2,500 shares of AstraZeneca stock in a transaction dated Monday, September 14th. The stock was bought at an average cost of £121.21 per share, with a total value of £303,025. Insiders own 0.15% of the company’s stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.